Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Trial Profile

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Sodium-glucose transport protein inhibitors
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EXSCEL
  • Sponsors Amylin Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company
  • Most Recent Events

    • 13 Nov 2023 Results assessing high throughput proteomic profiling performed using the SomaLogic SomaScan platform in 5473 patients with type 2 diabetes enrolled in the EXSCEL clinical trial, presented at the American Heart Association Scientific Sessions 2023.
    • 01 Jun 2023 Results assessing the sex differences in the characteristics and outcomes in participants with type 2 diabetes, with or without cardiovascular disease, published in the Diabetes, Obesity and Metabolism.
    • 31 Oct 2022 According to a SomaLogic media release, data from the trial will be presented at the American Heart Association Scientific Sessions 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top